Product Name :
BCI-121
Description:
BCI-121 is a SMYD3 inhibitor that impairs the proliferation of cancer cell.
CAS:
432529-82-3
Molecular Weight:
340.22
Formula:
C14H18BrN3O2
Chemical Name:
1-[(4-bromophenyl)carbamoyl]methylpiperidine-4-carboxamide
Smiles :
NC(=O)C1CCN(CC(=O)NC2C=CC(Br)=CC=2)CC1
InChiKey:
KSUYPIXCRPCPGF-UHFFFAOYSA-N
InChi :
InChI=1S/C14H18BrN3O2/c15-11-1-3-12(4-2-11)17-13(19)9-18-7-5-10(6-8-18)14(16)20/h1-4,10H,5-9H2,(H2,16,20)(H,17,19)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.Atorvastatin medchemexpress
Additional information:
BCI-121 is a SMYD3 inhibitor that impairs the proliferation of cancer cell.|Product information|CAS Number: 432529-82-3|Molecular Weight: 340.22|Formula: C14H18BrN3O2|Chemical Name: 1-[(4-bromophenyl)carbamoyl]methylpiperidine-4-carboxamide|Smiles: NC(=O)C1CCN(CC(=O)NC2C=CC(Br)=CC=2)CC1|InChiKey: KSUYPIXCRPCPGF-UHFFFAOYSA-N|InChi: InChI=1S/C14H18BrN3O2/c15-11-1-3-12(4-2-11)17-13(19)9-18-7-5-10(6-8-18)14(16)20/h1-4,10H,5-9H2,(H2,16,20)(H,17,19)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : ≥ 100 mg/mL (293.G36 custom synthesis 93 mM).PMID:33334188 |Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|BCI-121 significantly inhibits SMYD3-substrate interaction and chromatin recruitment and is effective in reducing proliferation in various cancer cells types. BCI-121 significantly reduces proliferation of HT29 (by 46%) and HCT116 (by 54%) cells at 72 h and decreases the expression levels of SMYD3 target genes. SMYD3 preferentially methylates histone H4, and the presence of BCI-121 impairs SMYD3-mediated H4 in vitro methylation. Cancer cells treated with BCI-121 show a significant reduction in their growth ability and accumulated in the S phase of the cell cycle. Cells treated with BCI-121 shows a dose-dependent relationship between SMYD3 impairment and both inhibition of proliferation and reduction of targeted methyl marks (H4K5me and H3K4me2). BCI-121 shows antiproliferative properties in cancer cell lines overexpressing SMYD3 and, in general, replicated the effects of SMYD3-targeted RNAi. Experiments performed in cancer cells show that BCI-121 prevents SMYD3 recruitment on the promoters of its target genes and this event is correlated with reduced gene expression.|Products are for research use only. Not for human use.|